Alnylam Pharmaceuticals ALNY Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's net income?
- Alnylam Pharmaceuticals (ALNY) reported net income of $205.99M in Q1 2026.
- How has Alnylam Pharmaceuticals's net income changed year-over-year?
- Alnylam Pharmaceuticals's net income increased by 1228.7% year-over-year, from -$18.25M to $205.99M.
- What is the long-term trend for Alnylam Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's net income has grown at a -24.4% compound annual growth rate (CAGR), from -$852.82M to $278.1M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.